FDA has renewed and expanded its licenses of Certara’s biosimulation software with more than 400 user licenses of the company’s Simcyp and Phoenix platforms. A company announcement says 11 FDA divisions and offices use the Certara software for internal research and to independently analyze, verify, and review regulatory submissions.
